Access cutting-edge endometrial cancer treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Access endometrial cancer specialists in New Haven at no cost
This study follows strict safety protocols and ethical guidelines
All study-related endometrial cancer treatment provided free
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
Sponsor: Gilead Sciences
Check if you qualify for this endometrial cancer clinical trial in New Haven, CT
If you're searching for endometrial cancer treatment options in New Haven, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced endometrial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.